Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00761709

Enrollment

104

Registered

2008-09-29

Start date

2009-07-31

Completion date

2009-10-31

Last updated

2014-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Open-Angle Glaucoma

Keywords

Open Angle Glaucoma, Ocular Hypertension

Brief summary

The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.

Interventions

DRUGAL-39256 Ophthalmic Suspension, 1%

DRUGLatanoprost Ophthalmic Solution, 0.005%

DRUGVehicle

Inactive ingredients used as a placebo comparator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosed with open-angle glaucoma or ocular hypertension. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Females of childbearing potential. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in IOP	Week 4

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026